ARCA BIOPHARMA INC (ABIO)
US00211Y5069 - Common Stock
Overall ABIO gets a fundamental rating of 3 out of 10. We evaluated ABIO against 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ABIO as it has an excellent financial health rating, but there are worries on the profitability. ABIO has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year ABIO has reported negative net income.
ABIO had a negative operating cash flow in the past year.
In the past 5 years ABIO always reported negative net income.
In the past 5 years ABIO always reported negative operating cash flow.
1.2 Ratios
ABIO has a better Return On Assets (-21.27%) than 77.82% of its industry peers.
The Return On Equity of ABIO (-22.10%) is better than 85.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.27% | ||
| ROE | -22.1% | ||
| ROIC | N/A |
ROA(3y)-24.11%
ROA(5y)-31.22%
ROE(3y)-25.36%
ROE(5y)-33.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ABIO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ABIO has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ABIO has been increased compared to 5 years ago.
There is no outstanding debt for ABIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
ABIO has an Altman-Z score of 8.70. This indicates that ABIO is financially healthy and has little risk of bankruptcy at the moment.
ABIO has a Altman-Z score of 8.70. This is amongst the best in the industry. ABIO outperforms 84.33% of its industry peers.
There is no outstanding debt for ABIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 8.7 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
ABIO has a Current Ratio of 26.61. This indicates that ABIO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 26.61, ABIO belongs to the top of the industry, outperforming 95.95% of the companies in the same industry.
ABIO has a Quick Ratio of 26.61. This indicates that ABIO is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 26.61, ABIO belongs to the best of the industry, outperforming 95.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 26.61 | ||
| Quick Ratio | 26.61 |
3. Growth
3.1 Past
The earnings per share for ABIO have decreased strongly by -13.18% in the last year.
EPS 1Y (TTM)-13.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-79.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
ABIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
ABIO has a Yearly Dividend Yield of 67.21%, which is a nice return.
The stock price of ABIO dropped by -35.14% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
ABIO's Dividend Yield is rather good when compared to the industry average which is at 9.33. ABIO pays more dividend than 99.82% of the companies in the same industry.
ABIO's Dividend Yield is rather good when compared to the S&P500 average which is at 2.33.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 67.21% |
5.2 History
ABIO is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2YN/A
EPS Next 3YN/A
ARCA BIOPHARMA INC
NASDAQ:ABIO (8/30/2024, 8:00:00 PM)
After market: 2.48 +0.08 (+3.33%)2.4
-0.1 (-4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.05%
Inst Owner Change0%
Ins Owners61.11%
Ins Owner Change0%
Market Cap34.82M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 67.21% |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.07 | ||
| P/tB | 1.07 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.5
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.47
OCFYN/A
SpS0
BVpS2.24
TBVpS2.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.27% | ||
| ROE | -22.1% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-24.11%
ROA(5y)-31.22%
ROE(3y)-25.36%
ROE(5y)-33.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 26.61 | ||
| Quick Ratio | 26.61 | ||
| Altman-Z | 8.7 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)92.92%
Cap/Depr(5y)95.75%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-13.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-79.73%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-16.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y58.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.85%
OCF growth 3YN/A
OCF growth 5YN/A